Direct Comparison of Spinal Cord Stimulator Parameter Settings
May 15, 2024 updated by: Case Western Reserve University
(Primary)
To compare the clinical effects and side effects of two different stimulation strategies that do not produce any sensory percept (1000 Hz and placebo) on clinical benefit for electrodes implanted for chronic pain as measured by the Visual Analog Pain Scale for back and leg pain, the Brief Pain Inventory, the 36-Item Short Form Survey (SF-36), and the Pain Vigilance and Awareness Questionnaire.
(Secondary)
- To compare the clinical effects of the subthreshold (paresthesia-free) stimulation patterns with conventional (paresthesia-producing) stimulation patterns to evaluate the necessity of paresthesias and current amplitudes on clinical benefit for pain.
- To identify the ability of subthreshold high-frequency to improve axial pain or the affective component of pain.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This is a prospective, randomized, double-blind study of different stimulation patterns in patients undergoing implantation of neurostimulator systems for chronic medically intractable neuropathic pain.
Research participants will be individuals who have undergone implantation of neurostimulator electrodes into the spinal column or peripheral nervous system for clinical treatment of neuropathic pain.
All patients will already have undergone empiric programming of the stimulator using conventional settings (typically 40-60 Hz, 350-450 usec pulse width).
However, other stimulation parameters, including high-frequency stimulation, are also feasible and FDA-approved using the implanted device, and it is possible to do this without producing a sensory percept, which makes it possible to test efficacy in a double blind manner.
For this study, two different stimulation parameters will be tested during four two-week periods: 1000 Hz and placebo.
Clinical response and side effect profile for each setting will be measured.
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44122
- University Hospitals Case Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18-75 years
- Diagnosis of chronic neuropathic pain for which placement of electrodes into the spinal column is planned for clinical indications (failed back surgery syndrome, peripheral neuropathy or complex regional pain syndrome)
- History of implantation of spinal cord stimulation system with rechargeable implanted neurostimulator
Exclusion Criteria:
- Significant dementia or other condition preventing informed consent by the patient.
- Current drug or alcohol abuse or dependence.
- Uncontrolled depression or anxiety or failure to pass psychological screening for spinal cord stimulation.
- Inability or unwillingness to cooperate with clinical testing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: High-Frequency Stimulation, Then Placebo Stimulation
Participants first receive sub-threshold high-frequency spinal cord stimulation (1200 Hz frequency, 200 μsec pulse width, and an amplitude 90% of the threshold for detection of a sensory percept) for 2 weeks.
After a 2-week washout period, they then receive sham spinal cord stimulation (1200 Hz at 0 V amplitude) for 2 weeks.
|
Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
|
|
Sham Comparator: Placebo Stimulation, Then High-Frequency Stimulation
Participants first receive sham spinal cord stimulation (1200 Hz at 0 V amplitude) for 2 weeks.
After a 2-week washout period, they then receive sub-threshold high-frequency spinal cord stimulation (1200 Hz frequency, 200 μsec pulse width, and an amplitude 90% of the threshold for detection of a sensory percept) for 2 weeks.
|
Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual Analog Pain Scale
Time Frame: 8 weeks
|
Assessment of overall degree of back and leg pain during each phase of stimulation (ie conventional baseline stimulation, high-density stimulation, conventional "washout" stimulation, and sham stimulation).
Scores range from 0 - 100, with a higher score indicating more pain.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Brief Pain Inventory (BPI)
Time Frame: 8 weeks
|
The BPI assesses pain at its "worst," "least," "average," and "now" (current pain).
Each item is rated on a scale of 0 - 10 with 10 indicating higher levels of pain.
For purposes of this outcome measure, we focused on "now" (current pain)
|
8 weeks
|
|
Change in SF-36
Time Frame: 8 weeks
|
The SF-36 is a measure of quality of life, with scores ranging from 0 - 100, with higher scores indicating a higher quality of life.
|
8 weeks
|
|
Pain Vigilance and Awareness Questionnaire (PVAQ)
Time Frame: 8 weeks
|
The PVAQ is a measure of vigilance and attention to pain.
Total scores can range from 0 to 90, with higher scores indicating more pain vigilance.
|
8 weeks
|
|
Number of Patients With Side Effects of Stimulation
Time Frame: 8 weeks
|
Incidence of side effects of stimulation
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jennifer A Sweet, MD, University Hospitals Cleveland Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2015
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
August 1, 2015
Study Registration Dates
First Submitted
December 23, 2021
First Submitted That Met QC Criteria
March 8, 2022
First Posted (Actual)
March 17, 2022
Study Record Updates
Last Update Posted (Actual)
May 21, 2024
Last Update Submitted That Met QC Criteria
May 15, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- 10-13-29
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.